Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Craig Portell, MD
University of Virginia
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
10 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Winship Cancer Institute of Emory University
Atlanta, Georgia, United States
- Sidney Kimmel Comprehensive Cancer Center at John Hopkins
Baltimore, Maryland, United States
- Mayo Clinic
Rochester, Minnesota, United States
- Washington University School of Medicine
St Louis, Missouri, United States
- Rutgers Cancer Institute of Nj
New Brunswick, New Jersey, United States
- Fox Chase
Philadelphia, Pennsylvania, United States
- Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States
- University of Virginia
Charlottesville, Virginia, United States
- Gunderson Health System Cancer Center
La Crosse, Wisconsin, United States
- University of Wisconsin
Madison, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 27 Dec 2017
- Primary completion
- 3 May 2021
- Completion
- 6 Jan 2023
- Last update posted
- 23 May 2025
- Registered enrollment
- 56
- Registry id
- NCT03113422
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.